Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Noriyoshi Iriyama, MD PhD, Kei-Ji Sugimoto, Eriko Sato, MD PhD, Tomoiku Takaku, MD PhD, Michihide Tokuhira, Tomonori Nakazato, MD PhD, Maho Ishikawa, MD, Hiroyuki Fujita, MD PhD, Yuta Kimura, MD, Isao Fujioka, MD, Norio Asou, MD PhD, Masahiro Kizaki, MD PhD, Norio Komatsu, MD PhD, Yoshihiro Hatta, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2018) 132 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2018-99-111732

Published: 2018

Journal Articles

Clinical Entity and Outcomes of Therapy-Related Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: Surveillance By the Chronic Myeloid Leukemia Cooperative Study Group

Noriyoshi Iriyama, MDPhD, Tomoiku Takaku, MD, PhD, Eriko Sato, Maho Ishikawa, Tomonori Nakazato, Kei-Ji Sugimoto, MD PhD, Hiroyuki Fujita, MD PhD, Michihide Tokuhira, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2016) 128 (22): 3084.

https://doi.org/10.1182/blood.V128.22.3084.3084

Published: 2016

Journal Articles

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Naoto Takahashi, MD PhD FJSIM, Tetsuzo Tauchi, MDPhD, Kunio Kitamura, MD PhD, Koichi Miyamura, MD PhD, Yoshio Saburi, MD PhD, Yasuhiko Miyata, MD PhD, Yoshihiro Hatta, Fumihiko Kimura, MD, Satoru Takada, MD, Tetsuya Fukuda, MD PhD, Katsumichi Fujimaki, Maho Ishikawa, Itaru Matsumura, MDPhD, Noriko Usui, MD, PhD, Kensuke Usuki, MDPhD, Yukio Kobayashi, MD PhD, Tomoki Naoe, MD PhD

Blood (2015) 126 (23): 4035.

https://doi.org/10.1182/blood.V126.23.4035.4035

Published: 2015

Journal Articles

Serum Erythropoietin Dose Not Participate in Anemia That Persists in CML Patients after MMR Achievement by Imatinib Mesylate Therapy

Maho Ishikawa, MD, PhD, Fumiharu Yagasaki, MD, PhD, Daisuke Okamura, MD, Tomoya Maeda, MD, PhD, Naoki Takahashi, MD, PhD, Nobutaka Kawai, MD, PhD, Akira Matsuda, MD, PhD, Itsuro Jinnai, MD, PhD, Masami Bessho, MD, PhD

Blood (2008) 112 (11): 4274.

https://doi.org/10.1182/blood.V112.11.4274.4274

Published: 2008

Journal Articles

Proline-Rich Tyrosine Kinase-2 (PYK2): A New Target for the Treatment of Hematopoietic Neoplasms with TEL-FGFR3 Fusion or FGFR3 Active Mutation.

Daisuke Okamura, Fumiharu Yagasaki, Tomoya Maeda, Maho Ishikawa, Itsuro Jinnai, Masami Bessho

Blood (2007) 110 (11): 3360.

https://doi.org/10.1182/blood.V110.11.3360.3360

Published: 2007

Journal Articles

Karyotypic Instability Is Common in t(8;21) AML at Relapse.

Tomoya Maeda, Fumiharu Yagasaki, Daisuke Okamura, Maho Ishikawa, Nobutaka Kawai, Itsuro Jinnnai, Masami Bessho

Blood (2006) 108 (11): 4452.

https://doi.org/10.1182/blood.V108.11.4452.4452

Published: 2006

Journal Articles

Roles of Bax, Bcl-xL and Bcl-2 in TEL-FGFR3 Associated Oncogenic Property.

Daisuke Okamura, MD, Fumiharu Yagasaki, MD, PhD, Tomoya Maeda, MD, PhD, Maho Ishikawa, MD, Itsurou Innai, MD, PhD, Masami Bessho, MD, PhD

Blood (2005) 106 (11): 4380.

https://doi.org/10.1182/blood.V106.11.4380.4380

Published: 2005

Journal Articles

Combination of PP1/PP2 and LY294002 Induce Apoptosis Efficiently to TEL-FGFR3 Transfected Ba/F3 Cells.

Daisuke Okamura, MD, Fumiharu Yagasaki, MD, PhD, Tomoya Maeda, MD, PhD, Maho Ishikawa, MD, Itsurou Jinnai, MD, PhD, Masami Bessho, MD, PhD

Blood (2005) 106 (11): 4465.

https://doi.org/10.1182/blood.V106.11.4465.4465

Published: 2005

Journal Articles

Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML

Tomoya Maeda, Fumiharu Yagasaki, Maho Ishikawa, Naoki Takahashi, Masami Bessho

Blood (2005) 105 (5): 2115–2123.

https://doi.org/10.1182/blood-2003-12-4290

Published: 2005

Journal Articles

A Novel Fusion, KIAA0379 (Ankyrin Repeat Domain 28) to NUP98 in an Adult MDS/AML with a t(3;5;11)(p25;q35;p15).

Maho Ishikawa, Fumiharu Yagasaki, Daisuke Okamura, Tomoya Maeda, Yuichi Sugahara, Motohiro Misumi, Katsuhiko Yoshida, Yuichi Nakamura, Nobutaka Kawai, Akira Matsuda, Itsuro Jinnai, Masami Bessho

Blood (2004) 104 (11): 4278.

https://doi.org/10.1182/blood.V104.11.4278.4278

Published: 2004

NARROW

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Clinical Entity and Outcomes of Therapy-Related Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: Surveillance By the Chronic Myeloid Leukemia Cooperative Study Group

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Serum Erythropoietin Dose Not Participate in Anemia That Persists in CML Patients after MMR Achievement by Imatinib Mesylate Therapy

Proline-Rich Tyrosine Kinase-2 (PYK2): A New Target for the Treatment of Hematopoietic Neoplasms with TEL-FGFR3 Fusion or FGFR3 Active Mutation.

Karyotypic Instability Is Common in t(8;21) AML at Relapse.

Roles of Bax, Bcl-xL and Bcl-2 in TEL-FGFR3 Associated Oncogenic Property.

Combination of PP1/PP2 and LY294002 Induce Apoptosis Efficiently to TEL-FGFR3 Transfected Ba/F3 Cells.

Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML

A Novel Fusion, KIAA0379 (Ankyrin Repeat Domain 28) to NUP98 in an Adult MDS/AML with a t(3;5;11)(p25;q35;p15).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only